Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema

Eye

Volumn 23, Issue 3, 2009, Pages 616-618

  Ozkiris A ^a,b  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Diabetic macular oedema; Intravitreal bevacizumab; Primary treatment

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; OUTCOME ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAOCULAR DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; TOMOGRAPHY; VITREOUS BODY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; TOMOGRAPHY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 62549101271     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.40     Document Type: Article

References (33)

1. Pelzek C, Lim JI. Diabetic macular edema: review and update. Ophthalmol Clin North Am 2002; 15: 555-563.
2. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14: 223-232.
3. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-2664.
4. Ozkiris A, Evereklioglu C, Oner A, Erkilic K. Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema. Doc Ophthalmol 2004; 109: 139-145.
5. Ozkiris A, Evereklioglu C, Erkilic K, Tamcelik N, Mirza E. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004; 14: 543-549.
6. Ozkiris A, Erkilic K, Koc A, Mistik S. Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy. Br J Ophthalmol 2007; 91: 69-73.
7. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94: 761-774.
8. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22: 200-207.
9. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-927.
10. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002; 134: 214-229.
11. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 2001; 132: 369-377.
12. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002; 47: S263-S269.
13. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969.
14. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
15. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 865-881.
16. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26: 994-998.
17. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054-1056.
18. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 155-158.
19. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26: 1006-1013.
20. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
21. Holladay JT. Proper method for calculating average visual acuity. J Refr Surg 1997; 13: 388-391.
22. Zambarakji HJ, Evans JE, Amoaku WM, Vernon SA. Reproducibility of volumetric measurements of normal maculae with the Heidelberg retina tomograph. Br J Ophthalmol 1998; 82: 884-891.
23. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005; 40: 63-68.
24. Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2004; 242: 184-185.
25. Cunningham Jr ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D0Amico DJ et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
26. Costa RA, Jorge R, Calucci D, Melo Jr LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-149.
27. Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol 2006; 124: 1365.
28. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley Jr MA. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006; 26: 882-888.
29. Ziemssen F, Grisanti S, Bartz-Schmidt KU. The international intravitreal bevacizumab safety survey. Br J Ophthalmol 2006; 90: 1440-1441.
30. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007; 143: 601-606.
31. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.
32. Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007; 245(6): 917-918.
33. Mason III JO, Albert Jr MA, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006; 26: 356-357.